Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2011-06-16 M&A Activity
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Medivir holds 94 per cent of the shares in BioPhausia following the expiry of the final acceptance period
M&A Activity Classification · 99% confidence The document is explicitly titled as a "Press Release" dated June 16, 2011, announcing that Medivir holds 94% of BioPhausia shares following an acquisition offer and that it is initiating a compulsory acquisition procedure and requesting de-listing. This content describes a significant corporate action related to ownership change and subsequent procedural steps (compulsory acquisition, de-listing request). This falls under the category of major corporate events that are often announced via press release. While it relates to share ownership, it is not a routine Director's Dealing (DIRS) or a Major Shareholding Notification (MRQ) which typically reports crossing a specific threshold. It is an announcement detailing the final outcome of a takeover bid and subsequent mandatory actions. Since it is a press release announcing a major corporate event (takeover completion and compulsory acquisition initiation) that doesn't fit perfectly into the other specific categories like M&A Activity (TAR) which usually covers the proposal/bid itself, or Share Issue (SHA), the most appropriate general category for a significant, non-standard regulatory announcement that isn't a core financial report (10-K, IR, ER) is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements. However, given the context of a takeover completion and compulsory acquisition, it strongly relates to Capital/Financing Update (CAP) or M&A Activity (TAR). Since the core action is the completion of an offer and initiation of compulsory acquisition following a takeover, TAR (M&A Activity) is a strong candidate, but the document focuses heavily on the *result* and the *next steps* (compulsory acquisition/de-listing) rather than the initial M&A proposal. Given the nature of the announcement (a press release detailing the finalization of an acquisition offer and subsequent mandatory steps), and lacking a specific 'Takeover Completion' code, RNS is the safest fallback for a general regulatory press release. Re-evaluating the definitions: TAR is for merger *proposals* or *takeover bids*. This is the *conclusion* of the bid. Since it involves significant changes in share structure and control, and is a formal announcement, RNS is the best fit as a general regulatory announcement.
2011-06-16 English
Påminnelse: Sista dag för accept av budet på BioPhausia är den 14 juni – kommer inte att förlängas
M&A Activity Classification · 98% confidence The document is a press release dated June 13, 2011, titled "Reminder: Last day to accept the offer for BioPhausia is June 14 – will not be extended." It explicitly discusses the deadline for accepting a takeover bid (bud) made by Medivir for BioPhausia. This subject matter—a takeover bid or merger proposal—directly corresponds to the definition of M&A Activity (TAR). Although it is a press release, its core content is about a specific corporate transaction (takeover bid) rather than just announcing the publication of a report (RPA) or being a general regulatory filing (RNS). Therefore, TAR is the most specific and appropriate classification.
2011-06-13 Swedish
Reminder: last day for acceptance of the offer for BioPhausia is 14 June – will not be extended
M&A Activity Classification · 98% confidence The document is a press release dated June 13, 2011, titled "Reminder: last day for acceptance of the offer for BioPhausia is 14 June – will not be extended." This clearly indicates an announcement related to a takeover bid or merger proposal concerning Medivir's offer for BioPhausia. This aligns directly with the definition for M&A Activity (TAR). Although it is a press release, its specific content relates to a takeover/merger offer, making TAR a more precise classification than the general Regulatory Filings (RNS) or Report Publication Announcement (RPA). The document length (3899 chars) is substantial enough to be the primary announcement, not just a notice that the announcement exists.
2011-06-13 English
Medivir fullföljer budet på BioPhausia och förlänger acceptfristen
AGM Information Classification · 99% confidence The document is a press release dated June 1, 2011, detailing the completion of a takeover bid (Erbjudandet) by Medivir for BioPhausia. It announces that the offer has been accepted by approximately 92% of shareholders, the offer is being finalized, and the acceptance period is being extended. It also mentions the issuance of new shares as consideration and the intent to delist BioPhausia. This content strongly relates to corporate actions involving mergers, acquisitions, and capital structure changes resulting from a takeover bid. This fits best under the 'M&A Activity' category (TAR), as it is the primary subject of the announcement, rather than a general regulatory filing (RNS) or a capital change (CAP), which is usually for fundraising or splits. Since the document is a full announcement detailing the results and next steps of a takeover, it is not a Report Publication Announcement (RPA).
2011-06-01 Swedish
Medivir completes the offer for BioPhausia and extends the acceptance period
M&A Activity Classification · 98% confidence The document is explicitly titled as a "Press Release" dated June 1, 2011, detailing the completion of an offer by Medivir to acquire BioPhausia, including the acceptance rates and extension of the offer period. This concerns a significant corporate transaction, specifically a takeover/merger activity. The content focuses entirely on the mechanics, results, and next steps of the acquisition offer. This aligns directly with the definition for M&A Activity (TAR). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it describes a specific, major transaction.
2011-06-01 English
Medivir offentliggör tillägg till erbjudandehandling avseende budet på BioPhausia samt förlänger acceptfristen
M&A Activity Classification · 98% confidence The document is a press release dated May 23, 2011, titled "Medivir offentliggör tillägg till erbjudandehandling avseende budet på BioPhausia samt förlänger acceptfristen" (Medivir publishes supplement to the offer document regarding the bid for BioPhausia and extends the acceptance period). This clearly indicates an announcement related to a takeover bid or merger activity (Medivir's bid for BioPhausia). This aligns directly with the definition for M&A Activity (TAR). Although it is a press release, the core subject matter is the M&A transaction itself (publishing a supplement to the offer document and extending the deadline), not just announcing the publication of a report (which would be RPA or RNS). Therefore, TAR is the most specific classification.
2011-05-23 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.